These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

409 related items for PubMed ID: 16513446

  • 1. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates.
    Lemma GL, Wang Z, Hamman MA, Zaheer NA, Gorski JC, Hall SD.
    Clin Pharmacol Ther; 2006 Mar; 79(3):218-30. PubMed ID: 16513446
    [Abstract] [Full Text] [Related]

  • 2. The effect of rifampin administration on the disposition of fexofenadine.
    Hamman MA, Bruce MA, Haehner-Daniels BD, Hall SD.
    Clin Pharmacol Ther; 2001 Mar; 69(3):114-21. PubMed ID: 11240975
    [Abstract] [Full Text] [Related]

  • 3. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics.
    Yasui-Furukori N, Uno T, Sugawara K, Tateishi T.
    Clin Pharmacol Ther; 2005 Jan; 77(1):17-23. PubMed ID: 15637527
    [Abstract] [Full Text] [Related]

  • 4. Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine.
    Tannergren C, Petri N, Knutson L, Hedeland M, Bondesson U, Lennernäs H.
    Clin Pharmacol Ther; 2003 Nov; 74(5):423-36. PubMed ID: 14586383
    [Abstract] [Full Text] [Related]

  • 5. A variant 2677A allele of the MDR1 gene affects fexofenadine disposition.
    Yi SY, Hong KS, Lim HS, Chung JY, Oh DS, Kim JR, Jung HR, Cho JY, Yu KS, Jang IJ, Shin SG.
    Clin Pharmacol Ther; 2004 Nov; 76(5):418-27. PubMed ID: 15536457
    [Abstract] [Full Text] [Related]

  • 6. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
    Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruce MA, Haehner-Daniels B, Hall SD.
    Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination.
    Kharasch ED, Walker A, Hoffer C, Sheffels P.
    J Clin Pharmacol; 2005 Jan; 45(1):79-88. PubMed ID: 15601808
    [Abstract] [Full Text] [Related]

  • 8. Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans.
    Schwarz UI, Gramatté T, Krappweis J, Berndt A, Oertel R, von Richter O, Kirch W.
    Clin Pharmacol Ther; 1999 Mar; 65(3):283-90. PubMed ID: 10096260
    [Abstract] [Full Text] [Related]

  • 9. Effect of St John's wort on the pharmacokinetics of fexofenadine.
    Wang Z, Hamman MA, Huang SM, Lesko LJ, Hall SD.
    Clin Pharmacol Ther; 2002 Jun; 71(6):414-20. PubMed ID: 12087344
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of fexofenadine enantiomers in healthy subjects.
    Miura M, Uno T, Tateishi T, Suzuki T.
    Chirality; 2007 Mar; 19(3):223-7. PubMed ID: 17230498
    [Abstract] [Full Text] [Related]

  • 11. Effects of liver fibrosis on verapamil pharmacokinetics in rats.
    Chen M, Xu D, Hu XL, Wang H.
    Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):287-94. PubMed ID: 17973928
    [Abstract] [Full Text] [Related]

  • 12. Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics.
    Yamada S, Yasui-Furukori N, Akamine Y, Kaneko S, Uno T.
    Ther Drug Monit; 2009 Dec; 31(6):764-8. PubMed ID: 19855315
    [Abstract] [Full Text] [Related]

  • 13. Clinical pharmacokinetics of fexofenadine enantiomers.
    Miura M, Uno T.
    Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):69-74. PubMed ID: 19947891
    [Abstract] [Full Text] [Related]

  • 14. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism.
    Shon JH, Yoon YR, Hong WS, Nguyen PM, Lee SS, Choi YG, Cha IJ, Shin JG.
    Clin Pharmacol Ther; 2005 Aug; 78(2):191-201. PubMed ID: 16084853
    [Abstract] [Full Text] [Related]

  • 15. St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism.
    Tannergren C, Engman H, Knutson L, Hedeland M, Bondesson U, Lennernäs H.
    Clin Pharmacol Ther; 2004 Apr; 75(4):298-309. PubMed ID: 15060508
    [Abstract] [Full Text] [Related]

  • 16. Effects of oral epigallocatechin gallate on the oral pharmacokinetics of verapamil in rats.
    Chung JH, Choi DH, Choi JS.
    Biopharm Drug Dispos; 2009 Mar; 30(2):90-3. PubMed ID: 19226653
    [Abstract] [Full Text] [Related]

  • 17. First-pass effects of verapamil on the intestinal absorption and liver disposition of fexofenadine in the porcine model.
    Petri N, Bergman E, Forsell P, Hedeland M, Bondesson U, Knutson L, Lennernäs H.
    Drug Metab Dispos; 2006 Jul; 34(7):1182-9. PubMed ID: 16621934
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.